| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Chris A Rallis is Director at FENC, with reported holdings spanning 2 companies. Chris A Rallis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $702K at current prices.
Our model assigns Chris A Rallis a middling insider score of 60/100, based on 17 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +0.6%.
Chris A Rallis's largest disclosed position is in FENC as Director, worth about $675K. The FENC filings lean toward selling, a net 39,163 shares.
Chris A Rallis has 34 Form 4 filings on record from August 2016 to June 2026, across 2 companies: Director at Fennec Pharmaceuticals (FENC), 2018–2026; Director at Tenax Therapeutics (TENX), 2016–2019.
The 54 reported transactions were 20 option exercises, 18 open-market sales, 11 option or other derivative awards and 4 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $297K.
The largest open-market sale was 8,346 shares of FENC at an average $7.04 on May 11, 2026, about $59K.
All 16 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 8,346 | $7.04 | $58,755.84 | -11.7% | +54.1% | - | |
| Oct 10, 2025 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,775 | $9.24 | $16,401.00 | -3.0% | -11.6% | +25.0% | |
| Jul 7, 2025 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,119 | $8.71 | $9,746.49 | -2.0% | +15.0% | +24.0% | |
| Apr 11, 2025 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,409 | $4.95 | $6,974.55 | -2.6% | +80.4% | +16.0% | |
| Feb 14, 2025 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,186 | $6.82 | $8,088.52 | -2.2% | -1.9% | +26.0% | |
| Dec 2, 2024 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 6,409 | $6.14 | $39,351.26 | -10.9% | +8.5% | +22.0% | |
| Oct 8, 2024 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,406 | $4.53 | $6,369.18 | -2.8% | +34.8% | +104.4% | |
| Jul 5, 2024 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 1,173 | $6.03 | $7,073.19 | -2.5% | -22.2% | +45.8% | |
| Apr 15, 2024 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 800 | $10.45 | $8,360.00 | -1.8% | -36.7% | -49.2% | |
| Mar 26, 2024 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 2,114 | $10.97 | $23,190.58 | -4.9% | -41.7% | -40.6% |